Nanobiotechnology-based treatment strategies for malignant relapsed glioma
文献类型：期刊论文
| 作者 | Qiu, Qiujun2,3; Ding, Xinyi2,3; Chen, Jixiang2,3; Chen, Sunhui1,5; Wang, Jianxin2,3,4 |
| 刊名 | JOURNAL OF CONTROLLED RELEASE
 |
| 出版日期 | 2023-06-01 |
| 卷号 | 358页码:681-705 |
| ISSN号 | 0168-3659 |
| 关键词 | Recurrent glioma Nanobiotechnology Drug delivery system Glioma microenvironment Anti-glioma immune response |
| DOI | 10.1016/j.jconrel.2023.05.016 |
| 通讯作者 | Wang, Jianxin(jxwang@fudan.edu.cn) |
| 英文摘要 | Gliomas are the most aggressive and lethal tumors of the central nervous system, for which few therapeutic options exist. Surgical resection is the primary treatment for most gliomas; however, tumor recurrence is nearly inevitable. Emerging nanobiotechnology-based strategies have shown great prospects for early glioma diagnosis, physiological barrier traversing, postoperative regrowth suppression, and microenvironment remodeling. Herein, we focus on the postoperative scenario and summarize the key properties of the glioma microenvironment, especially its immune peculiarities. We elucidate the challenges of managing recurrent glioma. We also discuss the potential of nanobiotechnology in addressing the therapeutic challenges of recurrent glioma, including optimizing the design of drug delivery systems, enhancing intracranial accumulation, and restoring the anti-glioma immune response. The development of these technologies offers new opportunities for accelerating the drug development process and treating recurrent glioma. |
| WOS关键词 | BLOOD-BRAIN-BARRIER ; CENTRAL-NERVOUS-SYSTEM ; GROWTH-FACTOR RECEPTOR ; SIALIC-ACID-CONJUGATE ; HYPOXIA-INDUCIBLE FACTORS ; ANTICANCER DRUG-DELIVERY ; TUMOR-DERIVED EXOSOMES ; REGULATORY T-CELLS ; IMMUNE-CHECKPOINT ; STEM-CELLS |
| 资助项目 | National Natural Science Foundation of China[81773911] ; National Natural Science Foundation of China[81690263] ; National Natural Science Foundation of China[81573616] ; Development Project of Shanghai Peak Disciplines-Integrated Medicine[20180101] |
| WOS研究方向 | Chemistry ; Pharmacology & Pharmacy |
| 语种 | 英语 |
| 出版者 | ELSEVIER |
| WOS记录号 | WOS:001012801000001 |
| 源URL | [http://119.78.100.183/handle/2S10ELR8/306370]  |
| 专题 | 中国科学院上海药物研究所 |
| 通讯作者 | Wang, Jianxin |
| 作者单位 | 1.Fujian Prov Hosp, Dept Pharm, Fuzhou 350001, Peoples R China 2.Fudan Univ, Sch Pharm, Dept Pharmaceut, Shanghai 201203, Peoples R China 3.Minist Educ, Key Lab Smart Drug Delivery, Shanghai 201203, Peoples R China 4.Fudan Univ, Inst Mat Med, Acad Chinese & Western Integrat Med, Shanghai 201203, Peoples R China 5.Fujian Med Univ, Shengli Clin Med Coll, Fuzhou 350001, Peoples R China |
| 推荐引用方式 GB/T 7714 | Qiu, Qiujun,Ding, Xinyi,Chen, Jixiang,et al. Nanobiotechnology-based treatment strategies for malignant relapsed glioma[J]. JOURNAL OF CONTROLLED RELEASE,2023,358:681-705. |
| APA | Qiu, Qiujun,Ding, Xinyi,Chen, Jixiang,Chen, Sunhui,&Wang, Jianxin.(2023).Nanobiotechnology-based treatment strategies for malignant relapsed glioma.JOURNAL OF CONTROLLED RELEASE,358,681-705. |
| MLA | Qiu, Qiujun,et al."Nanobiotechnology-based treatment strategies for malignant relapsed glioma".JOURNAL OF CONTROLLED RELEASE 358(2023):681-705. |
入库方式： OAI收割
来源：上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。